India’s Hyderabad based company Bharat Biotech, whose Covid vaccine ‘COVAXIN’ is in the advanced stage of the human trials in India is approaching to go global with the nations showing interest on its product. The potential vaccine is going strong in its trials as it has moved on to its phase third of the human trials after successful completion of the initial two phases of the trials on nearly 1,000 individuals. The vaccine developed in collaboration with the ICMR is seeking foreign partners in nearly 10 interested nations to introduce the vaccine and possibly to manufacture it locally. Currently in India, it will be going through the trials on about 25,000 to 26,000 individual participants in around 12 to 14 states.
Read More at REUTERS